Akero Therapeutics Analyst Ratings
Akero Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/12/2023 | 160% | UBS | $83 → $39 | Maintains | Buy |
| 10/11/2023 | 173.33% | JP Morgan | $62 → $41 | Maintains | Overweight |
| 10/11/2023 | 166.67% | HC Wainwright & Co. | $64 → $40 | Maintains | Buy |
| 10/11/2023 | 160% | Cantor Fitzgerald | $69 → $39 | Maintains | Overweight |
| 10/11/2023 | 120% | Morgan Stanley | $70 → $33 | Maintains | Overweight |
| 10/04/2023 | 360% | Cantor Fitzgerald | → $69 | Reiterates | Overweight → Overweight |
| 09/19/2023 | 360% | Cantor Fitzgerald | → $69 | Initiates Coverage On | → Overweight |
| 09/13/2023 | 300% | Evercore ISI Group | $50 → $60 | Maintains | Outperform |
| 09/05/2023 | 313.33% | JP Morgan | $49 → $62 | Maintains | Overweight |
| 08/28/2023 | 453.33% | UBS | → $83 | Initiates Coverage On | → Buy |
| 06/12/2023 | 366.67% | Morgan Stanley | $65 → $70 | Maintains | Overweight |
| 06/07/2023 | 326.67% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
| 05/17/2023 | 293.33% | Canaccord Genuity | $58 → $59 | Maintains | Buy |
| 05/16/2023 | 313.33% | HC Wainwright & Co. | $64 → $62 | Maintains | Buy |
| 03/21/2023 | 286.67% | Canaccord Genuity | $50 → $58 | Maintains | Buy |
| 03/20/2023 | 326.67% | HC Wainwright & Co. | → $64 | Reiterates | → Buy |
| 01/27/2023 | 333.33% | Morgan Stanley | → $65 | Upgrades | Equal-Weight → Overweight |
| 11/07/2022 | 166.67% | Morgan Stanley | $30 → $40 | Maintains | Equal-Weight |
| 11/07/2022 | 326.67% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
| 09/14/2022 | 100% | Morgan Stanley | $26 → $30 | Maintains | Equal-Weight |
| 09/14/2022 | 233.33% | Evercore ISI Group | $10 → $50 | Upgrades | In-Line → Outperform |
| 11/15/2021 | 93.33% | Morgan Stanley | $27 → $29 | Maintains | Equal-Weight |
| 11/15/2021 | 313.33% | HC Wainwright & Co. | $64 → $62 | Maintains | Buy |
| 10/19/2021 | 80% | Morgan Stanley | → $27 | Downgrades | Overweight → Equal-Weight |
| 09/10/2021 | 166.67% | B of A Securities | → $40 | Initiates Coverage On | → Buy |
| 08/16/2021 | 326.67% | HC Wainwright & Co. | $68 → $64 | Maintains | Buy |
| 03/23/2021 | 320% | Morgan Stanley | $70 → $63 | Maintains | Overweight |
| 03/23/2021 | 353.33% | HC Wainwright & Co. | $61 → $68 | Maintains | Buy |
| 03/18/2021 | 206.67% | Canaccord Genuity | $51 → $46 | Maintains | Buy |
| 03/17/2021 | 440% | Chardan Capital | $79 → $81 | Maintains | Buy |
| 03/17/2021 | 306.67% | HC Wainwright & Co. | $64 → $61 | Maintains | Buy |
| 02/26/2021 | 260% | Guggenheim | → $54 | Initiates Coverage On | → Buy |
| 11/13/2020 | 326.67% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
| 09/10/2020 | 366.67% | Morgan Stanley | → $70 | Initiates Coverage On | → Overweight |
| 07/20/2020 | 313.33% | HC Wainwright & Co. | $45 → $62 | Maintains | Buy |
| 07/07/2020 | 426.67% | Chardan Capital | → $79 | Initiates Coverage On | → Buy |
| 07/01/2020 | 200% | HC Wainwright & Co. | $33 → $45 | Maintains | Buy |
| 07/01/2020 | 220% | Jefferies | $31 → $48 | Maintains | Buy |
| 03/02/2020 | 120% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
| 02/10/2020 | 140% | Canaccord Genuity | → $36 | Initiates Coverage On | → Buy |
| 07/15/2019 | 86.67% | JP Morgan | → $28 | Initiates Coverage On | → Overweight |
| 07/15/2019 | 126.67% | Roth Capital | → $34 | Initiates Coverage On | → Buy |
| 07/15/2019 | 86.67% | Jefferies | → $28 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月12日 | 160% | 瑞銀集團 | $83→$39 | 維護 | 買 |
| 2023年10月11日 | 173.33% | 摩根大通 | $62→$41 | 維護 | 超重 |
| 2023年10月11日 | 166.67% | HC Wainwright公司 | $64→$40 | 維護 | 買 |
| 2023年10月11日 | 160% | 康託·菲茨傑拉德 | $69→$39 | 維護 | 超重 |
| 2023年10月11日 | 百分之一百二十 | 摩根士丹利 | $70→$33 | 維護 | 超重 |
| 10/04/2023 | 360% | 康託·菲茨傑拉德 | →$69 | 重申 | 超重→超重 |
| 2023/09/19 | 360% | 康託·菲茨傑拉德 | →$69 | 開始承保 | →超重 |
| 09/13/2023 | 百分之三百 | Evercore ISI集團 | $50→$60 | 維護 | 跑贏大盤 |
| 09/05/2023 | 313.33% | 摩根大通 | $49→$62 | 維護 | 超重 |
| 2023年08月28日 | 453.33% | 瑞銀集團 | →$83 | 開始承保 | →購買 |
| 2023/06/12 | 366.67% | 摩根士丹利 | $65→$70 | 維護 | 超重 |
| 06/07/2023 | 326.67% | HC Wainwright公司 | $62→$64 | 維護 | 買 |
| 2023年05月17日 | 293.33% | 卡納科特·格納奇 | $58→$59 | 維護 | 買 |
| 2023年05月16日 | 313.33% | HC Wainwright公司 | $64→$62 | 維護 | 買 |
| 03/21/2023 | 286.67% | 卡納科特·格納奇 | $50→$58 | 維護 | 買 |
| 03/20/2023 | 326.67% | HC Wainwright公司 | →$64 | 重申 | →購買 |
| 2023年1月27日 | 333.33% | 摩根士丹利 | →$65 | 升級 | 等重→超重 |
| 11/07/2022 | 166.67% | 摩根士丹利 | $30→$40 | 維護 | 等重 |
| 11/07/2022 | 326.67% | HC Wainwright公司 | $62→$64 | 維護 | 買 |
| 09/14/2022 | 100% | 摩根士丹利 | $26→$30 | 維護 | 等重 |
| 09/14/2022 | 233.33% | Evercore ISI集團 | $10→$50 | 升級 | 線內→表現優異 |
| 2021年11月15日 | 93.33% | 摩根士丹利 | $27→$29 | 維護 | 等重 |
| 2021年11月15日 | 313.33% | HC Wainwright公司 | $64→$62 | 維護 | 買 |
| 10/19/2021 | 80% | 摩根士丹利 | →$27 | 評級下調 | 超重→等重 |
| 09/10/2021 | 166.67% | B of A證券 | →$40 | 開始承保 | →購買 |
| 08/16/2021 | 326.67% | HC Wainwright公司 | $68→$64 | 維護 | 買 |
| 03/23/2021 | 320% | 摩根士丹利 | $70→$63 | 維護 | 超重 |
| 03/23/2021 | 353.33% | HC Wainwright公司 | $61→$68 | 維護 | 買 |
| 03/18/2021 | 206.67% | 卡納科特·格納奇 | $51→$46 | 維護 | 買 |
| 03/17/2021 | 440% | 查爾丹資本 | $79→$81 | 維護 | 買 |
| 03/17/2021 | 306.67% | HC Wainwright公司 | $64→$61 | 維護 | 買 |
| 02/26/2021 | 260% | 古根海姆 | →$54 | 開始承保 | →購買 |
| 11/13/2020 | 326.67% | HC Wainwright公司 | $62→$64 | 維護 | 買 |
| 09/10/2020 | 366.67% | 摩根士丹利 | →$70 | 開始承保 | →超重 |
| 07/20/2020 | 313.33% | HC Wainwright公司 | $45→$62 | 維護 | 買 |
| 07/07/2020 | 426.67% | 查爾丹資本 | →$79 | 開始承保 | →購買 |
| 07/01/2020 | 百分之二百 | HC Wainwright公司 | $33→$45 | 維護 | 買 |
| 07/01/2020 | 220% | 傑富瑞 | $31→$48 | 維護 | 買 |
| 03/02/2020 | 百分之一百二十 | HC Wainwright公司 | →$33 | 開始承保 | →購買 |
| 02/10/2020 | 140% | 卡納科特·格納奇 | →$36 | 開始承保 | →購買 |
| 2019年07月15日 | 86.67% | 摩根大通 | →$28 | 開始承保 | →超重 |
| 2019年07月15日 | 126.67% | 羅斯資本 | →$34 | 開始承保 | →購買 |
| 2019年07月15日 | 86.67% | 傑富瑞 | →$28 | 開始承保 | →購買 |
What is the target price for Akero Therapeutics (AKRO)?
Akero治療公司(AKRO)的目標價格是多少？
The latest price target for Akero Therapeutics (NASDAQ: AKRO) was reported by UBS on October 12, 2023. The analyst firm set a price target for $39.00 expecting AKRO to rise to within 12 months (a possible 160.00% upside). 19 analyst firms have reported ratings in the last year.
瑞銀於2023年10月12日報道了阿克羅治療公司(納斯達克：AKRO)的最新目標價。這家分析公司將AKRO的目標價設定為39美元，預計AKRO將在12個月內上漲(可能上漲160.00%)。去年有19家分析公司公佈了評級。
What is the most recent analyst rating for Akero Therapeutics (AKRO)?
Akero治療公司(AKRO)的最新分析師評級是多少？
The latest analyst rating for Akero Therapeutics (NASDAQ: AKRO) was provided by UBS, and Akero Therapeutics maintained their buy rating.
瑞銀提供了對阿克洛治療公司(納斯達克代碼：AKRO)的最新分析師評級，阿克羅治療公司維持其買入評級。
When is the next analyst rating going to be posted or updated for Akero Therapeutics (AKRO)?
Akero治療公司(AKRO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akero Therapeutics was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Akero Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Akero治療公司的上一次評級是在2023年10月12日提交的，所以你應該預計下一次評級將在2024年10月12日左右的某個時候提供。
Is the Analyst Rating Akero Therapeutics (AKRO) correct?
分析師對Akero Treeutics(AKRO)的評級正確嗎？
While ratings are subjective and will change, the latest Akero Therapeutics (AKRO) rating was a maintained with a price target of $83.00 to $39.00. The current price Akero Therapeutics (AKRO) is trading at is $15.00, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的AKRO評級保持不變，目標價在83.00美元至39.00美元之間。阿克羅治療公司(AKRO)目前的交易價格為15.00美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。